On Friday, Pyxis Oncology Inc (NASDAQ: PYXS) was 21.38% up from the session before settling in for the closing price of $1.45. A 52-week range for PYXS has been $0.83 – $5.55.
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -74.92%. When this article was written, the company’s average yearly earnings per share was at 1.43%. With a float of $48.09 million, this company’s outstanding shares have now reached $62.15 million.
Pyxis Oncology Inc (PYXS) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Pyxis Oncology Inc stocks. The insider ownership of Pyxis Oncology Inc is 22.76%, while institutional ownership is 38.03%. The most recent insider transaction that took place on Apr 21 ’25, was worth 14,362. Before that another transaction happened on Apr 17 ’25, when Company’s Director proposed sale 200 for $0.97, making the entire transaction worth $194.
Pyxis Oncology Inc (PYXS) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.26 earnings per share (EPS) during the time that was better than consensus figure (set at -0.33) by 0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 1.43% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 0.25% during the next five years compared to -74.92% drop over the previous five years of trading.
Pyxis Oncology Inc (NASDAQ: PYXS) Trading Performance Indicators
You can see what Pyxis Oncology Inc (PYXS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.29. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 32.01.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.59, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -1.18 in one year’s time.
